Reviewer is the scientific quality gate. Approve only after checking decision layer, graph, safety and references.
Source: Predictive Intelligence | Type: Plant / Molecule Evidence
Nodes: 5 | Edges: 4 | References: 20
Approve & Publish to KGMS RejectOpportunity score: 58/100
Clinical readiness: Moderate
| ID | Source evidence |
|---|---|
| REF_1 | Phytochemical Landscape: A Compound You Haven't Scored Yet Verification of the plant/compound framing doc, and why betulinic acid changes the ranking Prepared for: Dr. |
| REF_2 | Pravin Badhe, Swalife Biotech | Analysis date: 15 September 2026 1. |
| REF_3 | OSCC/HNSCC mechanistic evidence (KB cells: caspase-3/9, p53, ROS), and a large published potency dataset. |
| REF_4 | None of the bacosides/bacopasides/bacopasaponins clear more than 2 of these 4 bars. |
| REF_5 | The catch, and it's a real one for an IP strategy: betulinic acid is not distinctive to Bacopa monnieri. |
| REF_6 | It's one of the most-studied plant triterpenes in existence (birch bark, many other sources), already has a large prior-art footprint, and its presence in B. |
| REF_7 | Materials & verification This framing doc's numeric claims were spot-checked before charting anything. |
| REF_8 | PC9/SW620 Confirmed compound identity and cell lines (same source as prior report); IC50 values still not public Certain (identity) / NR (potency) This is the third framing document verified in this project today; all three had at least one number worth checking rather than taking on faith. |
| REF_9 | Results — charts with plain-language interpretation 3. |
| REF_10 | Count of individually named compounds in this framing document, grouped by chemical class. |
| REF_11 | In plain language: 15 of the 24 named compounds are dammarane saponins (bacosides/bacopasides/bacopasaponins) — that's the family your prior evidence report already scored. |
| REF_12 | Betulinic acid sits in a 3-compound 'triterpenoid aglycone' bucket that's easy to skim past. |
| REF_13 | Which named compounds actually have usable data Chart C2. |
| REF_14 | Evidence completeness per named compound: structure defined, non-oral cytotoxicity data, OSCC/HNSCC data, and a quantified IC50 anywhere. |
| REF_15 | In plain language: every saponin has a defined structure (that part of phytochemistry is solid), but only bacopaside II and bacopasaponin F clear 2 of the remaining 3 bars — and neither has OSCC data. |
| REF_16 | Betulinic acid's potency — and why the number moves so much Chart C3. |
| REF_17 | Betulinic acid IC50 ranges reported across different assay conventions (same molecule, different DMSO/vehicle handling). |
| REF_18 | In plain language: depending which paper you read, betulinic acid's potency is reported anywhere from ~1 µM to ~350 µM — a 300-fold spread that has nothing to do with biology and everything to do with solvent (DMSO%) and assay convention. |
| REF_19 | Caution] Any potency number you quote for this compound needs its assay conditions attached, or it's not comparable to anything. |
| REF_20 | Updated recommendation This doesn't replace the MCDA ranking in the first report — it adds a 6th candidate that wasn't scored: betulinic acid scores well on evidence completeness (OSCC data exists, unlike bacopaside II/bacopasaponin F) but poorly on 'novelty to B. |